{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:04:54Z","timestamp":1780031094349,"version":"3.53.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515110960, 2024A1515010834"],"award-info":[{"award-number":["2023A1515110960, 2024A1515010834"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a diverse malignant hematologic disorder with poor clinical outcomes. Increasing evidence suggests that metabolic reprogramming, particularly lipid metabolism, contributes to AML progression and may offer new opportunities for biomarker discovery and therapeutic targeting. However, lipid metabolism\u2013related hub genes with diagnostic and prognostic relevance in AML have not been systematically characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Expression profiles from GSE114868 and GSE9476 were analyzed to identify lipid metabolism-associated differentially expressed genes. Functional enrichment, single-sample gene set enrichment analysis (ssGSEA), weighted gene co-expression network analysis (WGCNA), machine-learning-based feature selection, diagnostic receiver operating characteristic (ROC) analysis, survival analysis, and immune infiltration analysis were performed. MTMR2 expression was further validated by RT-qPCR in an expanded clinical cohort of AML patients and healthy controls, and selected lipid-related clinical parameters were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lipid metabolism-related pathways were significantly altered in AML samples. Integration of differential expression analysis, WGCNA, LASSO regression, random forest analysis, and SVM-RFE identified MTMR2 as a candidate lipid metabolism-associated biomarker. MTMR2 was markedly upregulated in AML across independent datasets and showed good diagnostic performance. Kaplan-Meier analysis suggested an association between high MTMR2 expression and poorer overall survival. High MTMR2 expression was also associated with immune- and inflammation-related transcriptional features and with altered inferred immune-cell infiltration patterns. RT-qPCR analysis confirmed higher MTMR2 expression in AML samples, and exploratory clinical analysis showed lower ApoA1 and LDL-C levels and higher TG levels in AML patients than in healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies MTMR2 as a lipid metabolism-associated candidate biomarker in AML and provides preliminary clinical evidence supporting its increased expression and association with altered lipid-related parameters. These findings support further mechanistic and clinical validation of MTMR2 in larger independent AML cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1837038","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:46:20Z","timestamp":1780029980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of MTMR2 as an AML-associated candidate biomarker derived from lipid metabolism\u2013related transcriptomic analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Chenchen","family":"Liu","sequence":"first","affiliation":[{"name":"Zhanjiang Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People\u2019s Hospital of Zhanjiang)","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyuan","family":"Pan","sequence":"additional","affiliation":[{"name":"Zhanjiang Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People\u2019s Hospital of Zhanjiang)","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggui","family":"Chen","sequence":"additional","affiliation":[{"name":"Precision Clinical Laboratory, Zhanjiang Central Hospital, Guangdong Medical University (Central People\u2019s Hospital of Zhanjiang)","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyu","family":"Li","sequence":"additional","affiliation":[{"name":"Zhanjiang Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People\u2019s Hospital of Zhanjiang)","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhanjiang Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People\u2019s Hospital of Zhanjiang)","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/cells8080805","article-title":"Metabolic plasticity of acute myeloid leukemia","volume":"8","author":"Kreitz","year":"2019","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/moh.0000000000000853","article-title":"Unraveling lipid metabolism for acute myeloid leukemia therapy","volume":"32","author":"O'Brien","year":"2025","journal-title":"Curr Opin Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02645-z","article-title":"Targeting lipid metabolism in acute myeloid leukemia: Biological insights and therapeutic opportunities","volume":"39","author":"Dembitz","year":"2025","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/metabo13040467","article-title":"Therapy-resistant acute myeloid leukemia stem cells are resensitized to venetoclax + azacitidine by targeting fatty acid desaturases 1 and 2","volume":"13","author":"Culp-Hill","year":"2023","journal-title":"Metabolites"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1290968","article-title":"A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1655005","article-title":"Metabolic reprogramming and immune regulation in acute myeloid leukemia","volume":"16","author":"Hao","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429380394250217093030","article-title":"Exploring the immune-related molecular mechanisms underlying the comorbidity of temporal lobe epilepsy and major depressive disorder through integrated data set analysis","volume":"17","author":"Yan","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/0109298665351592250106062250","article-title":"Znf165: A pan-cancer biomarker with prognostic and therapeutic potential","volume":"32","author":"Lyu","year":"2025","journal-title":"Protein Pept Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2174\/0109298665341953240926041613","article-title":"Sgsm2 in uveal melanoma: Implications for survival, immune infiltration, and drug sensitivity","volume":"31","author":"Liang","year":"2024","journal-title":"Protein Pept Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/0113892029278082240118053857","article-title":"Tertiary lymphoid structures gene signature predicts prognosis and immune infiltration analysis in head and neck squamous cell carcinoma","volume":"25","author":"Xing","year":"2024","journal-title":"Curr Genomics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.4283-09.2010","article-title":"The phosphoinositide 3-phosphatase mtmr2 interacts with psd-95 and maintains excitatory synapses by modulating endosomal traffic","volume":"30","author":"Lee","year":"2010","journal-title":"J Neuroscience: Off J Soc For Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.209122","article-title":"Endosomal targeting of the phosphoinositide 3-phosphatase mtmr2 is regulated by an n-terminal phosphorylation site","volume":"286","author":"Franklin","year":"2011","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2006.06.001","article-title":"Myotubularin phosphatases: policing 3-phosphoinositides","volume":"16","author":"Robinson","year":"2006","journal-title":"Trends Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for rna-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"Clusterprofiler: An r package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","article-title":"Clusterprofiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"Gsva: Gene set variation analysis for microarray and rna-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (msigdb) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","article-title":"Wgcna: An r package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"B24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/A:1012487302797","article-title":"Gene selection for cancer classification using support vector machines","volume":"46","author":"Guyon","year":"2002","journal-title":"Mach Learn"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Software"},{"key":"B26","first-page":"18","article-title":"Classification and regression by randomforest","volume":"2","author":"Liaw","year":"2002","journal-title":"R News"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101592","article-title":"A cd36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in aml","volume":"5","author":"Guo","year":"2024","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/biomedicines11123186","article-title":"An overview on lipid droplets accumulation as novel target for acute myeloid leukemia therapy","volume":"11","author":"Nistic\u00f2","year":"2023","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the eln","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1837038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:46:26Z","timestamp":1780029986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1837038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1837038"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1837038","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1837038"}}